Impact of age and medical comorbidity on the effectiveness of implantable cardioverter-defibrillators for primary prevention

Circulation: Cardiovascular Quality and Outcomes

Volumn 2, Issue 1, 2009, Pages 16-24

  Chan, Paul S ^a   Nallamothu, Brahmajee K ^b   Spertus, John A ^a   Masoudi, Frederick A ^c   Bartone, Cheryl ^d   Kereiakes, Dean J ^d   Chow, Theodore ^d  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c DENVER HEALTH MEDICAL CENTER   (United States)

^d The Carl & Edyth Lindner Center for Research & Education   (United States)

Author keywords

Health outcomes; Implantable cardioverter defibrillator; Primary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SPIRONOLACTONE;

ADULT; AGE DISTRIBUTION; ARTICLE; CARDIOMYOPATHY; CLINICAL PRACTICE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEFIBRILLATOR; ELECTROPHYSIOLOGY; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HOLTER MONITORING; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; REIMBURSEMENT; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; AGE; AGED; CARDIOVERSION; CLINICAL TRIAL; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE COST; HEART ARRHYTHMIA; HEART LEFT VENTRICLE FUNCTION; INSTRUMENTATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATIENT SELECTION; PRIMARY PREVENTION; PROBABILITY; PROPENSITY SCORE; TIME; UNITED STATES;

AGE FACTORS; AGED; AGED, 80 AND OVER; ARRHYTHMIAS, CARDIAC; COMORBIDITY; COST-BENEFIT ANALYSIS; DEFIBRILLATORS, IMPLANTABLE; ELECTRIC COUNTERSHOCK; HEALTH CARE COSTS; HUMANS; KAPLAN-MEIERS ESTIMATE; MARKOV CHAINS; MIDDLE AGED; PATIENT SELECTION; PRIMARY PREVENTION; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 70349508573     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.108.807123     Document Type: Article

References (25)

1. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005; 352: 225-237.
2. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction. N Engl J Med. 2002; 346: 870-883.
3. Flay BR, Biglan A, Boruch RF, Castro FG, Gottfredson D, Kellam S, Moscicki EK, Schinke S, Valentine JC, Ji P. Standards of evidence: criteria for efficacy, effectiveness and dissemination. Prev Sci. 2005; 6: 151-175. (Pubitemid 43487950)
4. Davidson MH. Differences between clinical trial efficacy and real-world effectiveness. Am J Manag Care. 2006; 12: S405-S411. (Pubitemid 44865051)
5. Curtis LH, Al-Khatib SM, Shea AM, Hammill BG, Hernandez AF, Schulman KA. Sex differences in the use of implantable cardioverterdefibrillators for primary and secondary prevention of sudden cardiac death. JAMA. 2007; 298: 1517-1524. (Pubitemid 47529385)
6. Lee DS, Tu JV, Austin PC, Dorian P, Yee R, Chong A, Alter DA, Laupacis A. Effect of cardiac and noncardiac conditions on survival after defibrillator implantation. J Am Coll Cardiol. 2007; 49: 2408-2415. (Pubitemid 46962260)
7. Redberg RF. Disparities in use of implantable cardioverter- defibrillators: moving beyond process measures to outcomes data. JAMA. 2007; 298: 1564-1566.
8. Chow T, Kereiakes DJ, Bartone C, Booth T, Schloss EJ, Waller T, Chung E, Menon S, Nallamothu BK, Chan PS. Prognostic utility of microvolt T-wave alternans in risk stratifying patients with ischemic cardiomyopathy. J Am Coll Cardiol. 2006; 47: 1820-1827. (Pubitemid 44308234)
9. Bloomfield D, Hohnloser S, Cohen R. Interpretation and classification of microvolt T wave alternans tests. J Cardiovasc Electrophysiol. 2002; 13: 502-512.
10. Hinkle LE Jr, Thaler HT. Clinical classification of cardiac deaths. Circulation. 1982; 65: 457-464.
11. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol. 1983; 1: 710-719.
12. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983; 70: 41-55.
13. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997; 127: 757-763.
14. D'Agostino RB Jr. Propensity scores in cardiovascular research. Circulation. 2007; 115: 2340-2343.
15. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc. 1984; 79: 516-524.
16. Chan PS, Stein K, Chow T, Fendrick M, Bigger JT, Vijan S. Costeffectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverter-defibrillator placement in the MADIT-II-eligible population. J Am Coll Cardiol. 2006; 48: 112-121.
17. Gold M, Siegel J, Russell L, Weinstein M. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
18. National Vital Statistics Reports: United States Life Tables, 2002. Hyattsville, MD: National Center for Health Statistics, Centers for Disease Control and Prevention; 2002.
19. Chan PS, Hayward RA. Mortality reduction by implantable cardioverterdefibrillators in high-risk patients with heart failure, ischemic heart disease, and new-onset ventricular arrhythmia: an effectiveness study. J Am Coll Cardiol. 2005; 45: 1474-1481.
20. Chan PS, Chow T, Kereiakes D, Schloss EJ, Waller T, Eagle K, Hayward RA, Vijan S. Effectiveness of implantable cardioverter-defibrillators in patients with ischemic heart disease and left ventricular dysfunction. Arch Intern Med. 2006; 166: 2228-2233.
21. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo AL, Wilber D, Brown MW, Heo M; The Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 1996; 335: 1933-1940.
22. Buxton AE. Risk stratification for sudden death: do we need anything more than ejection fraction? Card Electrophysiol Rev. 2003; 7: 434-437.
23. Chow T, Kereiakes DJ, Bartone C, Booth T, Schloss EJ, Waller T, Chung E, Menon S, Nallamothu BK, Chan PS. Microvolt T-wave alternans identifies patients with ischemic cardiomyopathy who benefit from implantable cardioverter- defibrillator therapy. J Am Coll Cardiol. 2007; 49: 50-58.
24. Goldenberg I, Vyas AK, Hall WJ, Moss AJ, Wang H, He H, Zareba W, McNitt S, Andrews ML. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol. 2008; 51: 288-296.
25. Bloomfield DM, Steinman RC, Namerow PB, Parides M, Davidenko J, Kaufman ES, Shinn T, Curtis A, Fontaine J, Holmes D, Russo A, Tang C, Bigger JT Jr. Microvolt T-wave alternans distinguishes between patients likely and patients not likely to benefit from implanted cardiac defibrillator therapy: a solution to the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II conundrum. Circulation. 2004; 110: 1885-1889.